WO 2005/121076 PCT/US2005/017183
(DIARYL-METHYL)-MALONONITRILES AND THEIR USE AS ESTROGEN
RECEPTOR LIGANDS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims benefit to U.S. Provisional Application
Serial Number 60/572,859, filed May 19, 2004, which is incorporated herein by
reference in its entirety.
FIELD OF THE INVENTION
[0002] This invention relates to (diaryl-methyl)-malononitrile compounds, and their use as estrogen receptor ligands.
BACKGROUND OF THE INVENTION
[0003] The ability of ligands for the estrogen receptor to inhibit inflammatory gene expression (causing a reduction of cytokines, chemokines, adhesion molecules and inflammatory enzymes) is believed to provide a means to treat the inflammatory component of diseases such as atherosclerosis, myocardial infarction (MI), congestive heart failure (CHF), inflammatory bowel disease and arthritis. Other potential therapeutic indications for these type of molecules include type H diabetes (Cefalu, J. Womens Health & Gender-basedMed., 2001,10, 241 & Yuan et al9 Science, 2001, 293, 1673),osteoarthritis(Pelletieretal.,Arthr. & Rheum., 2001,44:1231 and Felson et al.,
1

WO 2005/121076 PCT/US2005/017183
Curr Opinion Rheum, 1998,10, 269) asthma (Chin-Chi Lin et al,Immunol Lett,, 2000, 73, 57), Alzheimer's disease (Roth, A. et al, J. Neurosci, Res., 1999, 57, 399) and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
[0004] A common component of these chronic inflammatory conditions is suspected to be infiltration of polymorphonuclear leukocytes and monocytes into the site of damage through increased expression of cytokines and adhesion molecules responsible for their recruitment. Overproduction of the cytokine interleukin (IL-6) has been associated with states of chronic inflammation (Bauer M. A., Herrmann F., Ann. Hematol, 1991, 62, 203). Synthesis of the IL-6 gene is induced by the transcription factor nuclear factor KB (NF-KB). Interference at this step in the inflammatory process is believed to effectively regulate the uncontrolled proliferative process that occurs in these chronic conditions.
[0005] In endothelial cells, 17ß-estradiol (E2) inhibits IL-l ß induced NF-KB reporter activity and IL-6 expression in an estrogen receptor (ER)-dependent fashion (Kurebayashi S. et al.,J. Steroid Biochem. Molec. Biol.,1991,60,11). This has been said to correlate with anti-inflammatory action of E2 in vivo as confirmed in different animal models of inflammation. In models of atherosclerosis, E2 was shown to protect endothelial cell integrity and function, and to reduce leukocyte adhesion and intimal accumulation (Adams, M. R. et al, Arterio., 1990,1051, Sullivan, T. R. et at, J. Clin. Invst 1995, 96, 2482, Nathan, L. et. al, Circ. Res., 1999, 55, 377). Similar effects of estrogen on the vascular wall have also been demonstrated in animal models of myocardial infarction (Delyani, J. A. et al, J. Molec. Cell Cardiol., 1996,28,1001) and congestive heart failure. Clinically, estrogen replacement therapy (ERT) has been demonstrated to reduce the risk of mortality in patients with both CHF(Reis et. al,J. Am. Coll Cardio., 2000, 36, 529) andMI (Grodstein, F. et al, Ann. Int. Med., 2000, 133, 933, Alexander et. al., J. Am. Coll Cardio., 2001, 38,1 and Grodstein F. et al, Ann. Int. Med, 2001,135,1). In ERT, clinical studies demonstrated an influence of E2 on the decrease in the production of P-amyloid 1-42 (Ap42), a peptide central for the formation of senile plaques in Alzheimer's disease (Schonknecht, P. et. al, Neurosci. Lett., 2001, 307,122).
[0006] 17-p-Estradiol, however, also strongly stimulates creatine kinase expression. Thus, in ERT some potential unwanted side effects, such as an increase risk of cardiovascular events in the first year of use, have been demonstrated (Hulley, S. et

WO 2005/121076

PCT/US2005/017183

at, J. Am. Med. Assoc, 1998, 280, 605) as well as proliferative effects on uterine and breast tissue.
SUMMARY OF THE INVENTION
[0007] The present invention relates to compounds that are able to serve as ligands for the estrogen receptor. Preferred compounds of this type are (diaryl-methyl)-malononitriles. In certain embodiments, such compounds are of formula:
N

wherein
R1, R.2, and R3 are each independently, hydrogen, halogen, alkyl, cycloalkyl, alkoxy, nitro, cyano, alkylthio, CF3, OCF3 or OH; and
R4 is hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl-methyl, or heterocyclyl-alkyl;
provided that at least one of R1, R2, R3, and R4 is other than H; and pharmaceutically acceptable salts, hydrates and solvates thereof.
[0008] In another aspect, the invention is drawn to pharmaceutical compositions that comprise one or more estrogen receptor ligands and a pharmaceutically acceptable carrier,
[0009] In yet other aspects, the invention concerns methods of treating or inhibiting chronic inflammatory disease in a mammal in need thereof, which comprise administering to said mammal an effective amount of a compound of the invention.
[0010] Such diseases include rheumatoid arthritis, spondyloarthropathies,
osteoarthritis, psoriatic arthritis, juvenile arthritis, inflammatory bowel disease, Crohn's
disease, ulcerative colitis, indeterminate colitis, psoriasis, asthma and chronic obstructive
pulmonary disease.
[0011] The invention is also directed to methods of treating or inhibiting stroke, ischemia, or reperfusion injury in a mammal in need thereof, which comprise
3

WO 2005/121076

PCT/US2005/017183

administering to said mammal an effective amount of a compound of the invention. In other embodiments, the invention concerns methods of lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal.
[0012] In yet other aspects, the compounds of the invention can be used for treating or inhabiting Alzheimer's disease, cognitive decline, senile dementia, or type II diabetes in a mammal.
DETAILED DESCRIPTION OF THE INVENTION
[0013] Preferred compounds of the present invention are those that block interleukin-1 (3 (IL-l ß ) induced nuclear factor KB (NF-KB) luciferase reporter activity or interleukin-6 (IL-6) expression in an ER dependent fashion in human endothelial cells. Compounds useful in the instant invention show preferably little or no proliferative
effects on uterine and breast tissue that is associated with estrogen in vivo. A lack of
estrogen side effects can be confirmed in vitro by the lack of expression of creatine
kinase (CK), a classic estrogen responsive gene. The compounds described herein are expected to prove useful for the treatment and prevention of chronic inflammatory diseases without stimulating uterine and breast cell proliferation as found with classic
estrogens.
i
[0014] Compounds of the present invention include (diaryl-methyl)-
malononitriles. In some aspects, the compounds may be represented by the formula:

wherein:
R1, R2, and R3 are each independently, hydrogen, halogen, alkyl, cycloalkyl, alkoxy, nitro, cyano, alkylthio, CF3, OCF3 or OH; and
R4 is hydrogen, alkyl, alkenyl, arylalkyl, cycloalkyl-methyl, or heterocyclyl-alkyl;'
4

WO 2005/121076 PCTYUS2005/017183
provided that at least one of R1, R2, R3, and R4 is other than H. and pharmaceutically acceptable salts, hydrates and solvates thereof.
[0015] In certain compounds, R4 preferably is H. In others, R4 is alkyl, alkenyl, arylalkyl, cycloalkyl-methyl, or heterocyclyl- alkyl.
[0016] In some embodiments, at least one of R1, R2, and R3 is halogen, alkyl,

cycloalkyl, alkoxy, nitro, cyano, alkylthio, CF3, OCF3 or OH.
[0017] R1 and R2 preferably are each, independently, hydrogen, halogen, alkyl, alkoxy, cyano, CF3 or OH in some compositions. In certain of these compositions, R1 and R2 are the same. In other compositions, R3 preferably is hydrogen, alkyl, alkenyl, alkylaryl, or heterocyclyl- methyl, in certain embodiments, R1 and R2 are each, independently, hydrogen, halogen, alkyl, or alkoxy. In still other embodiments, R3 is alkyl, allyl, benzyl.
[0018] In certain preferred compounds, R1 and R2 are each H and R3 is halogen, alkyl, alkoxy, cyano, CF3 or OH. In other compounds, R1 and R2 are each H and R3 is halogen, alkyl, or alkoxy. In certain of these compounds, R4 is H. In yet other compounds, R3 is methyl or methoxy.
[0019] Representative compounds of this invention include: 2-[(2-methoxyphenyl)(l-naphthyl)methyl]malononitrile, 2-[(3-methoxyphenyl)(l-naphthyl)methyl]malononitrile, 2-[(2-methylphenyl)(l-naphthyl)methyl]malononitrile, 2-[(4-methylphenyl)(l-naphthyl)methyl]malononitrile, 2-[(4-methoxyphenyi)(l-naphthyl)methyl]malononitrile,
r
2-[(2-methoxyphenyl)(l-naphtiiyl)methyl]-2-methyhnalononitrile, and
,
2-[di(l-naphthyl)methyl]malononitrile.
[0020] The invention is also directed to all or any of its stereoisomers and pharmaceutically acceptable salts of the compounds described herein. Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic,
:
phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable aids when a compound of this invention contains a basic moiety. Salts may also be formed from organic and inorganic bases, such as alkali metal salts (for example, sodium, lithium, or potassium) alkaline earth metal salts, ammonium salts, alkylam monium salts containing 1-6 carbon atoms or dialkylammonium salts containing
5

WO 2005/121076 PCT/US2005/017183
i
1-6 carbon atoms in each alkyl group, ;and trialkylammonium salts containing 1-6 carbon atoms in each alkyl group, when a compound of this invention contains an acidic moiety.
[0021] The term "alkyl", unless otherwise stated, refers to either a (C1-C6) straight chain or (C3-C6) branched-chain monovalent saturated hydrocarbon moiety. Examples oif saturated hydrocarbon alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as n-pentyl, n-hexyl, and the like.
[0022] The term "alkenyl", unless otherwise stated, refers to either a (C2-C6) straight chain or (C3-C6) branched-chain monovalent hydrocarbon moiety containing at least one double bond. Such hydrocarbon alkenyl moieties may be mono or polyunsaturated, and may exist in the E or Z configurations. The compounds of this invention are meant to include all possible E and Z configurations. Examples of mono or polyunsaturated hydrocarbon alkenyl moieties include, but are not limited to, chemical
groups such as vinyl, 2-propenyl, isopropenyl, crotyl, 2-isopentenyl, butadienyl, 2-
(butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), and higher homologs, isomers, and
the like.

[0023] The term "cycloalkyl", unless otherwise stated, refers to a monocyclic,
bicyclic, tricyclic, fused, bridged, or spiro monovalent saturated hydrocarbon moiety of

3-10 carbon atoms, wherein the carbon atoms are located inside or outside of the ring
system. Any suitable ring position of |the cycloalkyl moiety may be covalently linked to the defined .chemical structure. Examples of cycloalkyl moieties include, but are not limited to, chemical groups such as cyclopropyl, cyclopropylmethyl, cyclobutyl,
cyclopentyl, cyclohexyl, cyclohexyhnethyl, cyclohexylethyl, cycloheptyl, norbornyl,
1 1
adamantyl, |spiro[4.5]decanyl, and homologs, isomers, and the like.

[0024] The terms "halogen", employed alone or in combination with other1
terms, is defined herein as, unless otherwise stated, a fluorine, chlorine, bromine, or
iodine atom.
[0025] The term "aryl", employed alone or in combination with other terms, is defined herein as, unless otherwise stated, an aromatic carbocyclic moiety of up to 20 carbon atoms, e.g. 6-20 carbon atoms , which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently. Any suitable ring position of the aryl moiety may be covalently linked to the defined chemical structure. Examples of aryl moieties include, but are not limited to, chemical groups such as phenyl, 1-naphthyl, 2-naphthyl, dihydronaphthyl, tetrahydronaphihyl, biphenyl,
6

WO 2005/121076 PCT/US2005/017183
anthryl, phenanthryl, fluorenyl, indanyl, biphenylenyl, acenaphthenyl, acenaphthylenyl, and the like.
[0026] The term "arylalkyl", as used herein refers to the group -R-Ar where Ar is aryl and R is alkyl. Examples of arylalkyl moieties include, but are not limited to, chemical groups such as benzyl, 1-phenylethyl, 2-phenylethyl, diphenylmethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl, and homologs, isomers, and the like.
[0027] The term "hetero cyclic" or "heterocyclyl" includes 'heteroaryl" which, unless otherwise stated, refers to an aromatic heterocyclic ring system, which may be a single ring (monocyclic) or multiple rings (bicyclic, up to three rings) fused together or linked covalently. In some embodiments, heteroaryl groups have 4-20 carbon atoms. The rings may contain from one to four hetero atoms selected from nitrogen (N), oxygen (O), or sulfur (S), wherein the nitrogen or sulfur atom(s) are optionally oxidized, or the nitrogen atom(s) are optionally quarternized. Any suitable ring position of the heteroaryl moiety may be covalently linked to the defined chemical structure. In some embodiments, the heteroaryl group may be an aromatic 5-membered to 7-membered carbon-containing monocyclic ring having one to two heteroatoms which independently may be nitrogen, oxygen or sulfur. Examples of heteroaryl moieties include, but are not limited to, heterocycles such as furan, thiophene, pyrrole, N-methylpyrrole, pyrazole, N-methylpyrazole, imidazole, N-methylimidazole, oxazole, isoxazole, thiazole, isothiazole, lH-tetrazole, l~methyltetrazole, 1,3,4-oxadiazole, lH-l,2,4-triazole, 1-methyl-1,2,4-triazole, 1,3,4-triazole, l-memyl-l,3,4-iriazole,pyridine,pyrimidine, pyrazrne, pyridazine, benzoxazole, benzisoxazole, benzothiazole, benzofitran, benzothiophene, thianthrene, dibenzo[b,d]furan, dibenzo[b,d]thiophene, benzimidazole, N-methylbenzimidazole, indole, indazole, quinoUne, isoquinoline, quinazoline, quinoxaline, purine, pteridine, 9H-carbazole, p-carboline, and the like.
[0028] Heterocyclic chemical groups, as herein before defined, also include optionally saturated or partially saturated heterocyclic rings. Examples of saturated or partially saturated heterocyclic moieties include, but are not limited to, chemical groups such as azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzhnidazolyl, dihydrobenzofuranyl, dihydrobenzothienyl, dihydrobenzoxazolyl, dihydxoruranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrrazinyl, dihydropyrazolyl, dihydropyridinyl, dihyaropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl,
7

WO 2005/121076 PCT/US2005/017183
diirydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, dihydro-l,4-dioxanyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0029] The term "heterocyclyl-alkyr refers to the group -R-heterocycle where R is alkyl.
[0030] The term "alkoxy", unless otherwise stated, refers to either a (C1-C6) straight chain or (C3-C6) branched-chain hydrocarbon covalently bonded to an oxygen atom. Examples of alkoxy moieties include, but are not limited to, chemical groups such as methoxy, ethoxy, isopropoxy, sec-butoxy, tert-butoxy, decanoxy?, and homologs, isomers, and the like.
[0031] The term "alkylthio", unless otherwise stated, refers to either a (C1-C6) straight chain or (C3-C6) branched-chain hydrocarbon covalently bonded to a sulfur atom. Examples of alkylthio moieties include, but are not limited to, chemical groups such as methylthio, ethylthio, isopropylthio, sec-butylthio, tert-butylthio, and homologs, isomers, and the hke.
[0032] Each of the above terms (e.g., alkyl, aryl, heteroaryl) are meant to include unsubstituted, monosubstituted, and porysubstituted forms of the indicated radical or moiety. Substituents for each type of moiety are provided below.
[0033] Substituents for alkyl, alkenyl, cycloalkyl, alkylene?, the alkyl portion of arylalkyl and heterocyclyl-alkyl,, and acyl? moieties include -R', OR', =O, =NR', =N-0R', -NR'R", -SR', halogen -OC(O)R', -CO2RS -C(O)NR'R", -OC(O)NR'R", -NR"C(O)R\ -NR"CO2R', -NR'C(O)NR'R", -NH-C(NH2)=NH, -NR'C(NH2)-NH, -NH-C(NH2)=NR\ -S(O)R', -S(O)2R', -S(O)2NR'R", cyano, and nitro, where R' and R" each, independently, are hydrogen, unsubstituted (C1-C6)alkyl, unsubstituted (C3-C7)cycloalkyl, aryl, aryl-(C1-C3)alkyI, aryloxy-(C1-C3)alkyl, arylthio-(C1-C3)alkyl, heteroaryl, heteroaryl-(C1-C3)alkyl, heteroaryloxy-(C1-C3)alkyl, or heteroarylthio-(C1-C3)alkyl groups, or optionally taken together (when R' and R" are not hydrogen) form a ring?.
[0034] The aryl or heterocyclyl moieties, may be optionally mono-, di~ or tri-substituted with substituents. Representitive substitutents include -R', -OR', -SR', -C(O)R', -CO2R', -alkoxyalkyl, alkoxyalkyloxy, cyano, halogen, nitro, trifluoromethyl, trifluoromethoxy, -NR'R", alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, -S(O)R', -S(O)2R', -SO3R', -S(O)2NR'R", -CO2R', and C(O)NR'R", -OC(O)NR'R"5 -NR"C(O)R', -NR"CO2R', -NR'C(O)NR'R", -NH-C(NH2)=KH, -NR'C(NH2)=NH, -NH-
8

WO 2005/121076

PCT/US2005/017183

C(NH2)=NR', -S(O)R', and -S(O)2R'i where R' and R" each, independently, are hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, aryl, aryl-(C1-C3)alkyl, aryloxy-(C1-C3)alkyl, arylthio-(C1-C3)alkyl, heteroaryl, heteroaryl-(C1-C3)alkyl, heteroaryloxy-(C1-C3)alkyl, or
heteroarylthio-(C1-C3)alkyl groups, or optionally taken together (when R' and R" are not

hydrogen) form a ring.
[0035] The compounds of th'e present invention may contain an asymmetric atom, and some of the compounds may contain one or more asymmetric atoms or centers, which may thus give rise to optical isomers and diastereomers.
[0036] One synthetic approach to compounds of the present invention is described in Scheme 1.

[0037] The starting materials used herein are commercially available or are prepared by methods known to one skilled in the art. These methods can be found in standard references such as "Handbook of Reagents for Organic Synthesis" Volumes 1-4 (John Wiley & Sons, Chichester, UK, 1999) and Organic Reactions, Volumes 1-55 (John Wiley & Sons, NY).
[0038] Condensation of a malononitrile with an optionally substituted aromatic
or heteroaromatic aldehyde in the presence of a catalyst provides the intermediate (1) as
shown in Scheme 1. The catalyst can be a salt derived from an amine and a carboxylic
acid (e.g. ammonium formate or an amino acid such as alanine, (G. Jones, Organic
Reactions, 1967 15, 204; Y. Sumida, Polymer Journal, 1981 13, 521), a Lewis acid such
as titanium.tetrachloride in pyridine (W. Lehnert, Tetrahedron Lett., 1970, 54, 4723), or
9

WO 2005/121076

PCT/US2005/017183

an amine immobilized on a resin (J. Simpson, Tetrahedron Lett, 1999,40, 7031).
Recently, ionic liquids have also found use as media for base-catalyzed Knoevenagel
i
reactions. Michael addition of an aryl Grignard or lithium/copper (e.g. Gilman type) reagent (N. Laitif, J. Chem. Soc, 1974, 875; Gupte, J, Org. Chem., 1959,24, 1334) to the condensation product provides the substituted maiononitrile (2). Alkylation of the anion of (2) with an alkyl halide or sulfonate (A.A. Fadda, Ind. J. Chem., 1990, 29B, 171) provides the desired hisnitrile (3).
[0039] An alternative synthesis of Intermediate 2 (wherein Ar1 = naphthyl and Ar = phenyl) involves the synthesis of a diaryl methyl halide (or equivalent) and its use in a sequential alkylation of maiononitrile as shown in Scheme 2
Scheme 2



N
N
;i)NaH, DMF
_. >-
2)diarylmethyl
; x

I <2) 'Arf^Ar

N
; 2)RX X = I, Br, OTs, OAc, OMs, OTf
Ar
l)NaH, DMF
>»

R.4
N

I

[0040] The intermediate diarylmethyl-X in Scheme 2 can be obtained as shown in Scheme 3. The alcohol (3) is converted into a leaving group using methods known to one skilled |in the art (e.g. PI13P/CCI4, Ph3p/CBr4, methyltriphenoxyphosphonium iodide, TsCl/Pyr, MsCl/TEA, Ac2O/Pyr). '
10

WO 2005/121076

PCT/US2005/017183


[0041] An alternative synthesis of the compounds in which R4 is allyl or benzyl involves the synthesis of a 2-benzhydrylidene-malononitrile using methods known to one skilled in the art (e. g. Knoevenagel reaction) and subsequent addition of an allyl (or benzyl) starinane under the conclitionsiof Mizuno et al (J. Am Chem Soc 1988 110, 1288) as shown in Scheme 4.

EXAMPLES
Example 1
2-[(2-Methoxyphenyl)(l-iiaphthyl)methyl]maIononitrile
[0042] A flask was charged with (1 -naphthalenylmethylene)-propanedinitrile (408 mg, 2 mmol) and 10 mL anhydrous tetrahydroruran. To this stirred solution was added, at room temperature, 2-methoxy phenyl magnesium bromide (2.4 mL, 2.4 mmol, 1 M in tetrahydromran). The reaction was stirred 1.5 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Following purification on silica (20% ethyl
11

WO 2005/121076 PCT/US2005/017183
acetate/hexanes) 551 mg product was isolated as an off white foam.
1H NMR 400MHz (DMSO-d6): d 8.14 (d, 1H, J-8.05 Hz), 7.93 (m, 2H), 7.74 (d, 1H,
J=7.32 Hz), 7.60 (d, 1H, J=8.05 Hz), 7.53 (m, 2H), 7.27 (t, 1H, .1=7.85 Hz), 7.21 (dd, 1H,
J=7.81,1.71 Hz),7.09 (d, 1H, J=7.56 Hz), 6.89 (t, 1H, J=7.75 Hz), 6.02 (d, 1H, 1=10.25),
5.97 (d; 1H, J=10.49), 3.89 (s, 3H). MS (APCI) m/z 311 [M-H]";
Anal, calcd for C21H16N2O: C:80.75 H:5.16 N:8.97. Found: C:80.37 H:5.05 N:8.70.
Example 2 2-Naphthalen-l-yImethylene-malononitrile
[0043] 1-Naphthaldehyde (20 g, 128 mmol), malononitrile (10.15g, 153.7 mmol), piperidine (5.45 g, 64 mmol), 150 mL ethanol, and 100 mL toluene were combined in a flask equipped with a stirbar and refluxed with removal of water for 4 hours, after which the reaction was cooled and taken up in ethyl acetate. The organic layer was washed with 0.1 N hydrochloric acid, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered, evaporated to dryness. The residue was recrystallized from ethyl acetate to yield 8.80 g product as a crystalline solid, mp 165-167 °C;
1H. NMR 400MHz (DMSO-d6): d 9.36 (s, 1H), 8.25 (m, 2H), 8.17 (d, 1H, J=7.3 Hz),
8.06 (d, 1H, J=7.4 Hz), 7.68 (m, 3H)
MS (El) m/z (M)+ (204) [
Anal, calcd for C14H8N2 • 0.1 mol H2O: C:81.62 H:4.01 N:13.60. Found: C:81.76 H:3.76 N:13.75.
Example 3 2-[(3-Methoxyphenyl)(l-naphthyl)methyl]maIononitrile
[0044] A flask was charged with (l-naphthalenymiethylene)-propanedinitrile from Example 2 (408 mg, 2 mmol) and 10 mL anhydrous tetrahydrofuran. To this stirred solution was added, at room temperature, 3-methoxy phenyl magnesium bromide (2.4 mL, 2.4 mmol, 1 M in tetrahydrofuran). The reaction was stirred 1.5 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Following purification on silica (20% ethyl acetate/hexanes) 401 mg product was isolated as an off white foam. 1H NMR 400MHz (DMSO-d6): d 8.30 (d, 1H, J=8.29 Hz), 7.94 (m, 2H), 7.80 (d, 1H,
12

WO 2005/121076 PCT/US2005/017183
J=7.32 Hz), 7.62 (t, 1H, J=8.0 Hz), 7.54 (m, 2H), 7,25 (t, 1H, J=8.0 Hz), 7.09 (t, 1H,
J=1.95 Hz), 7.04 (d, 1H, J=7.08 Hz), 6.83 (dd, 1H, J-8.30 Hz, 0.73 Hz), 6.11 (d, 1H,
J=10.49 Hz), 5.87 (d, 1H, J-10.49 Hz), 3.69 (s, 3H);
MS(EI)?w/z,312(M)+;
Anal, calcd for C21H16N2O • 0.3 mol H2O C:79.37 H:5.27 N:8.82. Found: C:79.32
H:5.14N:8.62.
Example 4 2-[(2-MethylphenyI)(l-naphthyl)methyl]malonomtrile
[0045] A flask was charged with (l-naphthalenylmethylene)-propanedinitrile of Example 2 (408 rag, 2 mmol) and 10 mL anhydrous tetrahydrofuran. To this stirred solution was added, at room temperature, ortho-tolyl magnesium bromide (1.2 mL, 2.4 mmol, 2 M in tetrahydrofuran). The reaction was stirred 1.5 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Following purification on silica (20% ethyl acetate/hexanes) 455 mg product was isolated as an off white foam. 1H NMR 400MHz (DMSO-d6): d 8.38 (d, 1H, J=8.54 Hz), 7.96 (d, 1H, J=8.05 Hz), 7.91 (d, 1H, J=8.05 Hz), 7.60 (m, 1H), 7.54 (m, 2H), 7.46 (m, 2H), 7.24 (m, 1H), 7.20 (m, 2H), 6.04 (d, 1H, J=9.76 Hz), 5.95 (d, 1H, J=9.76 Hz), 2.30 (s, 3H); MS (APCI) m/z 295 [M-H]"; Anal, calcd for C21H16N2: C:85.11 H:5.44 N:9.45. Found: C:84.81 H:5.30 N:9.43.
Example 5 2-[(4-Methylphenyl)(l-naphthyl)methyl]maIononitrile
[0046] A flask was charged with (l-naphthalenyknethylene)-propanedinitxile of Example 2 (408 mg, 2 mmol) and 10 mL anhydrous tetrahydrofuran. To this stirred solution was added, at room temperature, 4-methylplienyl magnesium bromide (2.4 mL, 2.4 mmol, 1 M in tetrahydrofuran). The reaction was stirred 1.5 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Following purification on silica (15% ethyl acetate/hexanes) 116 mg product was isolated as an off white foam. 1HNMR 400MHz (DMSO-d6): d 8.25 (d, 1H, J=7.81 Hz), 7.92 (m, 2H), 7.78 (d, 1H,
13

WO 2005/121076 PCT/US2005/017183
J=7.32 Hz), 7.61 (t, 1H,.J=7.44 Hz), 7.52 (m, 2H), 7.37 (d, 2H, J=7.56 Hz), 7.13 (d, 2H,
J=7.81 Hz), 6.06 (d, J-9.76 Hz, 1H), 5.85 (d, J=10.49 Hz, 1H), 2.21 (s, 3H);
MS (APCI) m/z 295 [M-H]";
Anal, calcd for C21H16N2 • 0.15 mol H2O C:84.34 H:5.49 N:9.37. Found: C:84.03
H:5.54N:9.17.
Example 6 2-[(4-MethoxyphenyI)(l-naphthyl)methyl]malononitriIe
[0047] A flask was charged with (l-naphthalenylmethylene)-propanedinitrile of Example 2 (408 mg, 2 mmol) and 10 mL of anhydrous tetrahydrofuran. To this stirred solution was added, at room temperature, 4-methoxyphenyl magnesium bromide (4.8 mL, 2.4 mmol, 0.5 M in tetrahydrofuran). The reaction was stirred 1.5 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Following purification on silica (20% ethyl acetate/hexanes) 465 mg product was isolated as an off white foam. 1H NMR 400MHz (DMSO-d6): d 8.25 (m, 1H), 7.93 (m, 1H), 7.90 (s, 1H), 7.79 (d, 1H, J-7.32 Hz), 7.61 (t, 1H, J=7.81 Hz), 7.52 (m, 2H), 7.40 (d, 2H, J=8.79 Hz), 6.88 (d, 2H, J-8.79 Hz), 6.05 (d, 1H, J=10.49 Hz), 5.84 (d, 1H, J=10.49 Hz), 3.68 (s, 3H); MS (APCI) m/z 330 [M+NH4]+;
Anal, calcd for C21H16N2O • 0.4 mol H2O: C:78.93 H:5.30 N:8.77. Found: C:79.09 H:5.11N:8.47.
Example 7 2-[(2-Methoxyphenyl)(l-naphthyl)methyl]-2-methylmalononitriIe
[0048] 2-[(2-Methoxyphenyl)(l-naphthyl)methyl]malononitrile of Example 1 (196 mg, 0.63 mmol) was dissolved in 10 mL of tetrahydrofuran and cooled to -35°C. Potassium hexamethyldisilyl amide (1.14 mL, 0.75 mmol, 0.66 M in toluene) was added. The cooling bath was removed, and the reaction allowed to warm to room temperature, after which methyl iodide (0.078 mL, 125 mmol) was added. The reaction mixture was stirred 30 minutes, then quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over mgnesium sulfate, filtered, and evaporated to dryness. Following purification
on silica (20% ethyl acetate/hexanes)! and recrystallization from methanol, 104 mg

14

WO 2005/123076 PCT/US2005/017183
i '
product was isolated as a crystalline solid, mp 175-177 °C.
1H NMR 400 MHZ (DMSO-d6): d 8.10 (m, 1H), 7.95 (m, 3H), 7.64 (t, 1H, J=7.75 Hz),
7.52 (m, 2H), 7.31 (m, 2H), 7.14 (d, 1H, J=7.57 Hz), 6.91 (td, 1H, J=7.57 Hz, 0.98 Hz),
5.93 (s, 1H), 3.91 (s, 3H), 1.90 (s, 3H)1;
MS (APCI) m/z 327 [M+H]+;
Anal, calcd for C22H18N2O: C:80.96 H:5.56 N:8.58 Found: C:80.91 H:5.56 N:8.55.
Example 8 2-[Di(1-naphthyI)methyl]malononitriIe
[0049] A flask was charged with (l-naphthalenylmetiiylene)-propanedinitrile of Example 2 (408 mg, 2 mmol) and 10 mL anhydrous tetrahydrofuran. To this stirred solution was added, at room temperature, 1-naphthyl-magnesium bromide (12.5 mL, 2.5 mmol, 0.1 M in tetrahydrofuran). The reaction was stirred 2 hours, after which it was quenched with 1 N hydrochloric acid and taken up in ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate, brine, dried over magnesium sulfate, filtered, and evaporated to dryness. The residue was recrystallized from ethanol to yield 231 mg product as a crystalline solid, mp 179-181 °C.
1H KMR 400 MHz (DMSO-d6): d 8.41 (m, 2H), 7.96 (m, 2H), 7.91 (d, 2H, J=8.05 Hz), 7.60 (dd, 2H, J=7.32 Hz, 0.98 Hz), 7.53 (m 6H), 6.76 (d, 1H, J=9.52 Hz), 6.08 (d, 1H, J-9.27 Hz);
MS (APCI) m/z 331 [M-H]"; Anal, calcd for C24H16N2: C:86.72H:4.85N:8.43. Found: C:86.53 H:4.70N:8.51.
Example 9 2-(2-FIuoro-benzylidene)-malononitrile
[0050] Malononitrile (3.303 g, 50 mmol), 2-fluorobenzaldehyde (6.205 g, 50 mmol), Ig of molecular sieves, and 500 mg of a resin bound piperidine (described in Tetrahedron Lett, 1999,40, 7031-33) were placed in a vessel which was irradiated in a 300 W single mode microwave for 15 seconds. The reaction mixture was taken up in iso-propyl acetate, filtered, evaporated, taken up in dichloromethane, filtered through a pad of Magnasol, evaporated, and recrystallized from ethanol to yield 2.435 g of the title material as a crystalline solid, mp 117-118 °C. {Cam J. Chem., 1967, 45 1001-06) 1H NMR 400 MHz (DMSO-d6): d 8.58 (s, 1H), 8.04 (td, 1H, J=7.57 Hz, 1.71 Hz), 7.74
15

WO 2005/121076 PCT/US2005/017183
(m, 1H), 7.45 (m, 2H);
MS (APO) m/2 172 (M)";
Anal, calcd for C10H5FN2: C:69.77 H:2.93 N:16.27. Found: C:69.65 H:2.67 N:16.33.
Example 10
IN VITRO METHODS
Cells
[0051] T-175 flasks of 100% confluent HABCT-1 cells (immortalized human aortic endothelial cells) were washed with 8 ml of HBSS (HEPES buffered saline solution) and infected for four hours with 6 ml of a 1:10 dilution of Ad5-wt-hERa virus (an adenovirus transfection vector that mediates CMV promoter driven expression of human ERa) in phenol red free Endothelial Cell Basal medium (Clonetics, San Diego CA, Catalog # CC-3129) containing 0.25% bovine serum albumin (EBM-BSA). After four hoursi cells were washed with EBM-BSA and incubated overnight in the same medium. Following overnight incubation, cells were washed with EBM-BSA and infected for 2 hours with 6 ml of a 1:10 dilution of Ad5-3x(NFKB)Xuc virus (Adenovirus luciferase expression vector driven by 3 repeats oftheMHC NFKß site 5' to the thymidine kinase promoter) in EBM-BSA. After two hours, cells were washed and incubated at 34°C for 1 hour. Cells were then washed, trypsinized, counted and resuspended in 95%FBS / 5% dimethylsulfoxide at a concentration of 4x106 cells/ml, frozen as 1 or 5 ml aliquots in cryo-vials and stored at -150°C. Control (no ER infection) cells were processed as above without Ad5-wt-hERa virus infection.
IL-6 and Creatine Kinase Assays
[0052] ERa infected HAECT-1 cells or control cells were thawed, diluted 42x in warm EBM-BSA, plated into 96-well plates at 0.1 ml/well and incubated for 4h at 34°C. Test compounds were added to the cells as 2x stocks in EBM-BSA containing 2 ng/ml EL-1 ß (R&D Systems) and plates were returned to the incubator (34°C). After 15-20h, 100 µl aliquots of media were removed from the cells and assayed for IL-6 content using a BioSource human IL-6 ELISA Kit. Cells were subsequently washed with 300 µl of Dulbecco's phosphate buffered saline and lysed in 50 µl of Cell Culture Lysis Reagent (Promega). Luciferase was determined on a Wallac Victor2 Luminometer (Gaithersburg,
MD) using 10 µl of lysate and mixing with 100 µl of Promega Luciferase Assay reagent.
16

WO 2005/121076 PCT/US2005/017183
Creatine kinase was determined from the rate of increase in A340 following addition of
100 µl of CK assay reagent (Sigma, cat. No 47-10) to the remainder of the cell lysate.

Data Analyses
[0053] For IC50 and EC50 calculations, mean IL-6, hiciferase or CK
values versus logio of the compound concentration were fitted to a four parameter logistic equation. The IC50/ EC50 value, Hill slope1, upper and lower limits of the curve were iteratively estimated.
Mice
[0054] Ovariectomized C57BL/6 mice (16-20g) (Taconic) were separated into groups of 8. After 5-7 days of recuperation, the mice were fed a chow diet or an atherogenic diet (15.75% fat, 1.25% cholesterol and 0.5% sodium cholatc) (Purina diet #21539). EE or test compound was administered once daily by gavage in a methylcellulose/tween vehicle (0.1 ml per mouse) for 5 weeks. At the end of the experimental period, the liver was collected and uterine wet weight was recorded.
RNA Analysis
[0055] Liver total RNA was prepared by using Trizol reagent (BRL). Estrogen and compound regulation of NF-KB target genes were verified by real time R.T-PCR using an ABI PRISM 7700 Sequence Detection System according to the manufacturer's protocol (Applied Biosystems). The data was analyzed using the Sequence Detector vl.7 software (Applied Biosystems) and normalized to GAPDH using the Applied Biosystems primer set.
IN VITRO RESULTS
[0056] Table 1 summarizes the activities of E2 and several "anti-inflammatory estrogens" in the HAECT-1 NF-KB, IL-6 and creatine kinase assays in Ad5-wt-ER infected cells. Table 2 lists the activities of the same compounds in the HAECT-1 NF-KB and creatine kinase assays in uninfected cells.
17

WO 2005/121076

PCT/US2005/017183

Table 1. Effects of 17-P-estradioI on NF-KB, IL-6 and CK expression in Ad5-wt-ER infected HAECT-1 cells
NF-KB ILr6 CK
Compound IC»(nM) Efficacy (%1_ ICso(nM) Efficacy (%) IC50(nM) Efficacy (%1
E2 1 100 1.7 100 5.8 100
Ex 1 29 312 104 126 1218 118 8.7 27
Ex.3 853 138 1044 92 inactive
Ex.4 158 674 101147 1011 127 inactive
Ex.5 1661 154 inactive
Ex.6 1644 137
Ex.7 9.9 17.5 98 89 24 144 30.7 28
Ex.8 768 581 176 179 560 152
"Efficacy values are relative to the maximal inhibition (NF-KB or IL-6 assay) or stimulation (CK assay) observed with E2
Table 2. Effects of 17-p-estradiol on NF-KB and CK expression in non ER infected HAECT-1 cells
NF-KB CK
Compound IC50 (nM) Efficacy (%) IC50(nM) Efficacy (%)
E2 inactive inactive
Ex.1 inactive inactive
Ex.7 inactive inactive
[0057] E2 inhibits NF-KB and IL-6 expression in Ad5-wt-ER infected HAECT-1 cells with an IC50 value around 1 nM and induces expression of creatine kinase in the same cells with similar potency (5.8 nM) (Table 1). In contrast, the compounds of the instant invention inhibit NF-KB and IL-6 expression in Ad5-wt-ER infected HAECT-1 cells show reduced or no CK expression (Table 1). The above compounds inhibit NF-KB expression in an ER-dependent manner as indicated by their inactivity on IL-6 in HAECT-1 cells not infected with the Ad5-wt-ER virus (Table 2). The ability of the instant compounds to inhibit NF-KB and IL-6 expression without inducing CK activity (Table 1) is consistent with an anti-inflammatory activity in the absence of classic estrogenic activity.
Example 11
IN VIVO ACTIVITY
[0058] To determine the ability of estrogens to regulate the development of diet-induced inflammation in the liver, gene expression changes resulting from the atherogenic diet were monitored. Oyariectomized C57BL/6 mice were fed either a chow or atherogenic diet and treated daily with EE (0.01 mg/kg) or test compound
18

WO 2005/121076

PCT/US2005/017183

(10mg/kg) (Table 3). Real time RT-PCR analysis confirmed the atherogenic diet induction of mRNA for MHC invariant chain (MHI), VCAM-1, RANTES, and TNF-a and treatment with EE strongly suppressed the induction of these genes.
[0059] Treatment with the test compound did not result in a significant induction in uterine wet weight increase, an undesirable activity associated with EE (Table 3).
Table 3 Effects of EE (0.01 mg/kg/day) and test compound (10mg/kg/day) on uterine wet weight increase in C57BL/6 compared to vehicle control.

Uterine Wet Weight Increase
Compound Fold Increase Efficacy (%)
EE 5.0 100
Ex.7 2.2 18
Evaluation of test compounds using an ERE-reporter test procedure in MCF-7 breast cancer cells
[0060] Stock solutions of test compounds (usually 0.1 M) are prepared in DMSO and then diluted 10 to 100-fold with DMSO to make working solutions of 1 or 10
mM. The DMSO stocks are stored at either 4 °C (0.1 M) or-20 °C (< 0.1M). MCF-7 cells are passaged twice a week with growth medium [D-MEM/F-12 medium containing 10% (v/v) heat-inactivated fetal bovine serum, 1% (v/v) Penicillin-Streptomycin, and 2 mM grutaMax-1]. The cells are maintained in vented flasks at 37 °C inside a 5% CO2/95% humidified air incubator. One day prior to treatment, the cells are plated with growth medium at 25,000 cells/well into 96 well plates and incubated at 37 °C overnight. [0061] The cells are infected for 2 hr at 37 °C with 50 µl/well of a 1:10 dilution of adenovirus 5-ERE-tk-luciferase in experimental medium [phenol red-free D-MEM/F-12 medium containing 10% (v/v) heat-inactived charcoal-stripped fetal bovine serum, 1% (v/v) Penicillin-Streptomycin, 2 mM glutaMax-1, 1 mM sodium pyruvate]. The wells are then washed once with 150 µl of experimental medium. Finally, the cells are
19

WO 2005/121076 PCT/US2005/017183

treated for 24 hr at 37 °C in replicates of 8 wells/treatment with 150 µl/well of vehicle (< 0.1% v/v DMSO) or compound that is diluted = 1000-fold into experimental medium.
[0062] Initial screening of test compounds is done at a single dose of 1 pM that is tested alone (estrogen receptor agonist mode) or in combination with 0.1 nM 17 ß-estradiol (EC80o; estrogen receptor antagonist mode). Each 96 well plate also includes a vehicle control group (0.1% v/v DMSO) and an estrogen receptor agonist control group (either 0.1 or 1 nM 17 ß -estradiol). Dose-response experiments are performed in either the estrogen receptor agonist and/or estrogen receptor antagonist modes on active compounds in log increases from 10-14 to 10-5 M. From these dose-response curves, EC50 and IC50 values, respectively, are generated. The final well in each treatment
!
group contains 5 µl of 3 x 10-5 M ICI-182,780 (10-6 M final concentration) as an estrogen receptor antagonist control.
[0063] After treatment, the cells are lysed on a shaker for 15 min with 25 µl/well of IX cell culture lysis reagent (Promega Corporation). The cell lysates (20 µl) are transferred to a 96 well luminometer plate, and luciferase activity is measured in a MicroLumat LB 96 P luminometer (EG & G Berthold) using 100 µl/well of luciferase substrate (Promega Corporation). Prior to the injection of substrate, a 1 second background measurement is made for each well. Following the injection of substrate, '
luciferase activity is measured for 10 seconds after a 1 second delay. The data are
transferred from the luminometer to a Macintosh personal computer and analyzed using
the JMP software (SAS Institute); this program subtracts the background reading from the luciferase measurement for each well and then determines the mean and standard deviation of each treatment.
[0064] The luciferase data, are transformed by logarithms, and the Huber M-estimator is used to down-weight the outlying transformed observations. The JMP software is used to analyze the transformed and weighted data for one-way ANOVA

(Dunnett's test). The compound treatments are compared to the vehicle control results in the estrogen receptor agonist mode, or the positive estrogen receptor agonist control results (0.1 nM 17p-estradiol) in the estrogen receptor antagonist mode. For the initial single dose experiment, if the compound treatment results are significantly different from the appropriate control (p<0.05), then the results are reported as the percent relative to the 17 ß-estradiol control [i.e., ((compound - vehicle control)/(17 ß-estradiol control -
20

WO 2005/321076

PCT/US2005/017183

vehicle control)) x 100]. The JMP software is also used to determine the EC50 and/or IC50 values from the non-linear dose-response curves.
Evaluation of uterotrophic activity
[0065] Uterotrophic activity of a test compound can be measured according to the following standard pharmacological test procedures.
[0066] Procedure 1: Sexually immature (18 days of age) Sprague-Dawley rats are obtained from Taconic and provided unrestricted access to a casein-based diet
(Purina Mills 5K96C) and water. On day 19,20 and 21 the rats are dosed

subcutaneously with 17a-ethinyl-17 ß-estradiol (0.06 µg/rat/day), test compound or
vehicle (50% DMSO/50% Dulbecco's PBS). To assess estrogen receptor antagonist, compounds are coadministered with 17a-ethinyl-17 ß-estradiol (0,06 µg/rat/day). There are six rats/group and they are euthanized approximately 24 hours after the last injection by CO2 asphyxiation and pneumothorax. Uteri are removed and weighed after trimrning associated fat and expressing any internal fluid. A tissue sample can also be snap frozen for analysis of gene expression (e.g. complement factor 3 mRNA).
[0067] Procedure 2: Sexually immature (18 days of age) 129 SvE mice are obtained from Taconic and provided unrestricted access to a casein-based diet (Purina Mils 5K96C) and water. On day 22} 23,24 and 25 the mice are dosed subcutaneously

with compound or vehicle (corn oil).

There are six mice/group and they are euthanized

approximately 6 hours after the last injection by CO2 asphyxiation and pneumothorax. Uteri are removed and weighed after [trimming associated fat and expressing any internal fluid.
Evaluation of osteoporosis and lipid modulation fcardioprotection)
[0068] Female Sprague-Dawley rats, ovariectomized or sham operated, are
obtained 1 day after surgery from Taconic Farms (weight range 240 - 275 g). They are

housed 3 or 4 rats/cage in a room on a 12/12 (light/dark) schedule and provided with
i
food (Purina 5K96C rat chow) and water ad libitum. Treatment for all studies begin 1
day after arrival and rats are dosed 7 days per week as indicated for 6 weeks. A group of age matched sham operated rats not receiving any treatment serve as an intact, estrogen replete control group for each study.
[0069] All test compounds are prepared in a vehicle of 50% DMSO (JT Baker, Phillipsburg, NJ) / lx Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY) at
21

WO 2005/121076 PCT/US2005/017183
defined concentrations so that the treatment volume «s 0.1 mL/100 g body weight. 17 ß-estradiol is dissolved in corn oil (20 µg/mL) and. delivered subcutaneously, 0.1 mL/rat. All dosages are adjusted at three week intervals according to group mean body weight measurements, and given subcutaneously.
[0070] Five weeks after the initiation of treatment and one week prior to the termination of the study, each rat is evaluated for bont: mineral density (BMD). The total and trabecular density of the proximal tibia are evaluated in anesthetized rats using an XCT-960M (pQCT; Stratec Medizintechnik, Pforzheim, Germany). The measurements are performed as follows: Fifteen minutes prior to scanning, each rat is anesthetized with an inrraperitoneal injection of 45 mg/kg ketamine, 8.5 rng/kg xylazine, and 1.5 mg/kg acepromazine.
[0071] The right hind limb is passed through a polycarbonate tube with a diameter of 25 mm and taped to an acrylic frame with the ankle joint at a 90° angle and the knee joint at 180°. The polycarbonate tube is affixed to a sliding platform that maintains it perpendicular to the aperture of the pQCT. The platform is adjusted so that the distal end of the femur and the proximal end of the tibia is in the scanning field. A two dimensional scout view is run for a length of 10 mm and a line resolution of 0.2 mm. After the scout view is displayed on the monitor, the proximal end of the tibia is located. The pQCT scan is initiated 3.4 mm distal from this point. The pQCT scan is 1 mm thick, has a voxel (three dimensional pixel) size of 0.140 mm, and consists of 145 projections through the slice.
[0072] After the pQCT scan is completed, the image is displayed on the
monitor. A region of interest including the tibia but excluding the fibula is outlined. The
soft tissue is mathematically removed; using an iterative algorithm. The density of the
remaining bone (total density) is reported in mg/cm3. The outer 55% of the bone is mathematically peeled away in a concentric spiral. The density of the remaining bone (Trabecular density) is reported in mg/cm3.
[0073] One week after BMD evaluation the rats are euthanized by CO2 asphyxiation and pneumothorax, and blood is collected for cholesterol determination. The uteri are also removed and the weighed after trimming associated fat and expressing any luminal fluid. Total cholesterol is determined using a Boehringer-Mannheim Hitachi 911 clinical analyzer using the Cholesterol/HP kit. Statistics were compared using oneway analysis of variance with Dunnet's test.
22

WO 2005/121076

PCT/US2005/017183

Evaluation' of antioxidant activity
[0074] Porcine aortas are obtained from an abattoir, washed, transported in
chilled PBS, and aortic endothelial cells are harvested. To harvest the cells, the intercostal yessels of the aorta are tied off and one end of the aorta clamped. Fresh,
sterile filtered, 0.2% collagenase (Sigma Type 1) is placed in the vessel and the other end
i
of the vessel then clamped to form a closed system. The aorta is incubated at 37 °C for 15-20 minutes, after which the collagenase solution is collected and centrifuged for 5 minutes at 2000 x g. Each pellet is suspended in 7 mL of endothelial cell culture
medium consisting of phenol red freelDMEM/Ham's F12 media supplemented with
i
charcoal stripped FBS (5%), NuSerum (5%), L-glutamine (4 mM), penicillin-
ii
streptomycin (1000 U/ml, 100 µg/ml) and gentamycin (75 µg/ml), seeded in 100 mm petri dish and incubated at 37 °C in 5%CO2. After 20 minutes, the cells are rinsed with PBS and fresh medium added, this was repeated again at 24 hours. The cells are confluent after approximately 1 week. The endothelial cells are routinely fed twice a week and, when confluent, trypsinized and seeded at a 1:7 ratio. Cell mediated oxidation
of 12.5 µg/mL LDL is allowed to proceed in the presence of the compound to be

evaluated (5 µM) for 4 hours at 37 °G. Results are expressed as the percent inhibition of

the oxidatiye process as measured by the TBARS (thiobarbituric acid reactive
substances) method for analysis of free aldehydes [Yagi, Biochemical Medicine, 1976, 15, 212-6].
Progesterone receptor mRNA regulation standard pharmacological test procedure
[0075] This test procedure can be used to evaluate the estrogenic or antiestrogenic activity of compounds from this invention [Shughrue et al, Endocrinology, 1997, 138, 5476-5484].
Rat Hot Flush Test Procedure
[0076] The effect of test compounds on hot flushes can be evaluated in a

standard pharmacological test procedure which measures the ability of a test compound
to blunt the mcrease in tail skin temperature which occurs as morphine-addicted rats are
acutely withdrawn from the drug using naloxone [Merchenthaler et al, Maturitas, 1998

30, 307-16]. It can also be used to detect estrogen receptor antagonist activity by co-dosing test [compound with the reference estrogen.
23

WO 2005/121076 PCT/US2005/017I83
Evaluation of vasomotor function in isolated rat aortic rings
[0077] Sprague-Dawley rats (240-260 grams) are divided into 4 groups:
1. Normal non-ovariectomized (intact)
2. Ovariectomized (ovex) vehicle treated
3. Ovariectomized 17 ß-estradiol treated (1 mg/kg/day)
4. Ovariectomized animals treated with test compound (various doses)
[0078] Animals are ovariectomized approximately 3 weeks prior to treatment.
iEach animal receives either 17- ß estradiol sulfate (1 mg/kg/day) or test compound
suspended in distilled, deionized water with 1% tween-80 by gastric gavage. Vehicle treated animals received an appropriate volume of the vehicle used in the drug treated groups,
[0079] Animals are euthanized by CO2 inhalation and exsanguination. Thoracic aortae are rapidly removed and placed in 37 °C physiological solution with the following composition (mM): NaCl (54.7), KC1 (5.0), NaHCO3 (25.0), MgCl2 2H2O (2.5), D-glucose (11.8) and CaCl2 (0.2) gassed with CO2-O2, 95%/5% for a final pH of 7.4. The advantitia is removed from the outer surface and the vessel is cut into 2-3 mm wide rings. Rings are suspended in a 10 mL tissue bath with one end attached to the bottom of the bath and the other to a force transducer. A resting tension of 1 gram is placed on the rings. Rings are equilibrated for 1 hour, signals are acquired and analyzed.
[0080] After equilibration, the rings are exposed to increasing concentrations of phenylephrine (10-6 to l0-4M) and the tension recorded. Baths are then rinsed 3 times with fresh buffer. After washout, 200 mM L-NAME is added to the tissue bath and
equilibrated for 30 minutes. The phenylephrine concentration response curve is then
repeated.

Evaluation of cardioprotective activity
[0081] Apolipoprotein E-deficient C57/B1J (apo E KO) mice are obtained from Taconic Farms. All animal procedures are performed under strict compliance to IACUC guidelines. Ovariectomized female apo E KO mice, 4-7 weeks of age, are housed in shoe-box cages and were allowed free access to food and water. The animals are randomized by weight into groups (n=12-15 mice per group). The animals are dosed with test compounds or estrogen (17 ß-estradiol sulfate at 1 mg/kg/day) in the diet using a Precise-dosing Protocol, where the amount of diet consumed is measured weekly, and
24

WO 2005/121076 PCT/US 2005/017183
the dose adjusted accordingly, based on animal weight. The diet used is a Western-style diet (57U5) that is prepared by Purina and contains 0.50% cholesterol, 20% lard and 25 IU/KG Vitamin E. The animals are dosed/fed using this paradigm for a period of 12 weeks. Control animals are fed the Western-style diet and receive no compound. At the end of the study period, the animals are euthanized and plasma samples obtained. The hearts are perfused in situ, first with saline and then with neutral buffered 10% formalin solution.
[0082] For the determination of plasma lipids and lipoproteins, total cholesterol and triglycerides are determined using enzymatic methods with commercially available kits from Boehringer Mannheim and Wako Biochemicals, respectively and analyzed using the Boehringer Mannheim Hitachii 911 Analyzer. Separation and quantification of plasma lipoproteins were performed using FPLC size fractionation. Briefly, 50-100 mL of serum is filtered and injected into Superose 12 and Superose 6 columns connected in series and eluted at a constant flow rate with 1 mM sodium EDTA and 0.15 M NaCl. Areas of each curve representing VLDL, LDL and HDL are integrated using Waters Millennium™ software, and each lipoprotein fraction is quantified by multiplying the Total Cholesterol value by the relative percent area of each respective chromatogram peak.
[0083] For the quantification of aortic atherosclerosis, the aortas are carefully
isolated and placed in formalin fixative for 48-72 hours before handling. Atherosclerotic
lesions are identified using Oil Red O staining. The vessels are briefly destained, and
then imaged using a Nikon SMU800 microscope fitted with a Sony 3CCD video camera
system in concert with IMAQ Configuration Utility (National Instrument) as the image
capturing software. The lesions are quantified en face along the aortic arch using a
custom threshold utility software package (Coleman Technologies). Automated lesion
assessment is performed on the vessels using the threshold function of the program,
specifically on the region contained within the aortic arch from the proximal edge of the
brachio-cephalic trunk to the distal edge of the left subclavian artery. Aortic
atherosclerosis data are expressed as percent lesion involvement strictly within this
defined luminal area.
Evaluation of cognition enhancement
[0084] Ovariectomized rats (n=50) are habituated to an 8-arm radial arm maze for 10-min periods on each of 5 consecutive days. Animals are water-deprived prior to
25

WO 2005/121076 PCT/US2005/017183
habituationand testing. A 100 µL aliquot of water placed at the ends of each arm serves
i
as reinforcement. Acquisition of a win-shift task in the radial arm maze is accomplished
i i
by allowing the animal to have access to one baited arm. After drinking, the animal exits the arm and re-enters the central compartment, where it now has access to the previously visited arm or to a novel arm. A correct response is recorded when the animal chooses to enter a novel arm. Each animal is given 5 trials per day for 3 days. After the last acquisition trial, the animals are assigned to one of the following 4 groups:
1. Negative controls: injected with 10% DMSO/ sesame oil vehicle once daily for
6 days (1 mL/kg, SC)
2. Positive controls: injected with 17 ß-estradiol benzoate for 2 days and tested 4
days after the second injection (17 ß-estradiol benzoate at 10 µg/0.1 mL per rat)
3. Estradiol: 17 ß-estradiol will be injected daily for 6 days (20 µg/kg, SC)
4. Test compound: injected daily for 6 days (doses vary).
All injections will begin after testing on the last day of acquisition. The last injection for groups 1, 3; and 4 will take place 2 hours before testing for working memory.
[0085] The test for working memory is a delayed non-matching-to-sample task (DNMS) utilizing delays of 15, 30, or 60 seconds. This task is a variation of the acquisition task in which the rat is placed in the central arena and allowed to enter one arm as before. A second arm is opened once the rat traverses halfway down the first arm, and again the rat is required to choose this arm. When it has traveled halfway down this second arm, both doors are closed and the delay is instituted. Once the delay has expired, both of the original two doors, and a third novel door, are opened simultaneously. A correct response is recorded when the animal travels halfway down the third, novel arm. An incorrect response is recorded when the animal travels halfway down either the first or second arms. Each animal will receive 5 trials at each of the three delay intervals for a total of 15 trials per subject.
Evaluation of effect on pleurisy
[0086] The ability to reduce the symptoms of experimentally-induced pleurisy
in rats can be evaluated according to the procedure of Cuzzocrea [Endocrinology 141: 1455-63 (2000)].
Evaluation of protection against glutamate-induced cytotoxicity (neuroprotection) [0087] The neuroprotective activity of compounds of this invention can be
evaluated in an in vitro standard pharmacological test procedure using glutamate
26

WO 2005/121076

PCT/US2005/017183

challenge [Zaulyanov et al., Cellular & Molecular Neurobiology, 1999, 19, 705-18; Prokai et all, Journal of Medicinal Chemistry, 2001, 44, 110-4].
Evaluation in the Mammary End Bud Test Procedure
[0088] Estrogens are required for full ductal elongation and branching of the

mammary ducts, and the subsequent development of lobulo-alveolar end buds under the

influence of progesterone. In this test

procedure, the mammotrophic activity of selected

compounds of the invention can be evaluated according to the following standard pharmacological test procedure, Twenty-eight day old Sprague-Dawley rats (Taconic
Farms, Germantown, NY) are ovariectomized and rested for nine days. Animals are

housed under a 12-hour light/dark cycle, fed a casein-based Purina Laboratory Rodent Diet 5K96 (Purina, Richmond, IN) and allowed free access to water. Rats were then dosed subcutaneously for six days with vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / 50% 1x Dulbecco's Phosphate buffered saline (GibcoBRL, Grand Island, NY), 17 ß-estradibl (0.1 mg/kg) or test compound (20 mg/kg). For the final three days, rats are also dosed subcutaneously with progesterone (30 mg/kg). On the seventh day, rats are euthanised and a mammary fat pad excised. This fat pad is,analyzed for casein kinase II mRNA as a marker of end bud proliferation. Casein kinase II mRNA is anlayzed by real-time RT-PCR. Briefly, RNA is isolated following Trizol (GibcoBRL, Grand Island, NY) according to the manufacture's directions, Samples are treated with DNAse I using
DNA-free kit (Ambion), and casein kinase II mRNA levels are measured by real-time

RT-PCR using the Taqman Gold procedure (PE Applied Biosystems). A total of 50 ng
of RNA is analyzed in triplicate using casein kinase II specific primer pair (5' primer, CACACGGATGGCGCATACT, SEQ ID NO: 1; 3' primer, CTCGGGATGCACCATGAAG, SEQ ID NO: 2) and customized probe (TAMRA-
CGGCACTGGTTTCCCTCACATGCT-FAM, SEQ ID NO: 3). Casein kinase H mRNA
levels are normalized to 18s ribosomal RNA contained within each sample reaction
using primers and probe supplied by PE Applied Biosystems.
Evaluation in the HLA Rat Standard Pharmacological Test Procedure for inflammatory
bowel disease

[0089] Representative compounds can be evaluated in the HLA rat standard pharmacological test procedure which emulates inflammatory bowel disease in humans. The following briefly describes the procedure used and results obtained. Male HLA-B27
27

WO 2005/121076 PCT/US2005/017183
rats are obtained from Taconic and provided unrestrici.ed access to food (PMI Lab diet 5001) and water. Rats are dosed subcutaneously once per day with either vehicle (50%
DMSO / 50% 1x Dulbecco's Phosphate Buffered Salir e) or test compound (0.1 to 10
i mg/kg) forlat least one week. Stool quality is observed daily and graded according to the
following scale: Diarrhea = 3; soft stool = 2; normal s ool = 1. At the end of the study, serum is collected and stored at -70 °C. A section of colon is prepared for histological analysis and an additional segment is analyzed for myeloperoxidase activity.
[0090] For histological analysis, colonic tissue is immersed in 10% neutral buffered formalin. Each specimen of colon is separated into four samples for evaluation. The formalin-fixed tissues are processed in a Tissue Tek vacuum infiltration processor (Miles, Inc; West Haven, Connecticut) for paraffin embedding. The samples are sectioned at 5 urn and then stained with hematoxylin and eosin (H&E) for blinded histologic evaluations using a scale modified after Boughton-Smith. After the scores are completed the samples are unblinded, and data are tabulated and analyzed by ANOVA linear modeling with multiple mean comparisons. Sections of colonic tissue are evaluated for several disease indicators and given relative scores.
Evaluation in three models of arthritis
[0091] Lewis rat assay of adjuvant-induced arthritis. Sixty, female, 12 weeks old, Lewis rats are housed according to standard facility operating procedures. They receive a standard regimen of food and water ad libitum. Each animal is identified by a cage card indicating the project group and animal number. Each rat number is marked by indelible ink marker on the tail. At least 10-21 days before study they are anesthetized and ovariectomized by standard aseptic surgical techniques.
[0092] Freund's Adjuvant-Complete (Sigma Icomuno Chemicals, St. Louis,
MO) is used to induce arthritis, each mL containing 1 mg Mycobacterium tuberculosis
heat killed and dried, 0.85 mL mineral oil and 0.15 mL mannide monooleate Lot No.
084H8800.,
[0093] The following are examples of two test procedures. Inhibition test procedure: Thirty rats are injected intradermally with 0.1 mL of Freund's Adjuvant-Complete at the base of the tail. The animals are randomized to four groups, each group containing six rats. Each day, the groups receive vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / lx Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY)) or
28

WO 2005/121076

PCT/US2005/017183

test compound (0.1-10 mg/kg, administered subcutaneously). All rats begin treatment on
Dayl.
[0094] Treatment test procedure: Thirty rats are injected intradermally with 0.1 mL of Freund's Adjuvant-Complete at the base of the tail. The animals are randomized to four groups, each group containing six tats. Each day, the groups receive vehicle (50% DMSO (JT Baker, Phillipsburg, NJ) / 1x Dulbecco's phosphate saline (GibcoBRL, Grand Island, NY)) or test compound (0.1-10 mg/kg, administered subcutaneously). All rats begin treatment on Day 8 after adjuvant injection.
[0095] Statistical analysis is performed using Abacus Concepts Super ANOVA. (Abacus Concepts, Inc., Berkeley, CA). All of the parameters of interest are subjected to Analysis of Variance with Duncan's new multiple range post hoc testing between groups. Data are expressed throughout as mean ± standard deviation (SD), and differences are deemed significant if p<0.05.
[0096] The degree of arthritis severity is monitored daily in terms of the following disease indices: Hindpaw erythema, hindpaw swelling, tenderness of the joints, and movements and posture. An integer scale of 0 to 3 is used to quantify the level of erythema (0= normal paw, 1= mild erythema, 2— moderate erythema, 3= severe erythema) and swelling (0=normal paw, l=mild swelling, 2= moderate swelling, 3= severe swelling of the hind paw). The maximal score per day is 12.
[0097] At the end of the study the rats are euthanized with CO2, hindlimbs removed at necropsy and fixed in 10% buffered formalin, and the tarsal joints decalcified and embedded in paraffin. Histologic sections are stained with Hematoxylin and Eosin or Safrranin O - Fast Green stain.
[0098] Slides are coded so that the examiner is blinded to the treatment groups.

Synovial tissue from tarsal joints is evaluated based on synovial hyperplasia,
inflammatory cell infiltration, and panmus formation [Poole and Coombs, International

Archives of Allergy & Applied Immunology, 1997, 54, 97-113] as outlined below.

Category Grade
1 Syaovial lining cells
a. No change 0
b. Cells enlarged, slightly thickened 1
c. Cells enlarged, increase in numbers,.moderately thickened. No villus present 2
d. Cells enlarged, thickened. Villlus present 3
2 Fibroplasia
29

WO 2005/121076

PCT/US2005/017183

a. No change 0
b. Fibroplasia present under lining cells 1
c. Small areas of areolar tissue replaced by fibrous tissue 2
d. Replacement of areolar tissue by fibrous tissue 3
3. Inflammatory cells
a. Occasionally seen, scattered throughout selection 0
b. Cells present in small numbers in or just under lining cell layer and/or around blood vessels. 1
c. Small focal collection of cells may be present 2
d. Large numbers of cells present in capsule and in or under lining cell layers. Large foci often seen. 3
4. Pannus
a. Not detectable 0
b. Detectable 1
[0099] In addition, articular cartilage and bone is evaluated using Mankin's histological grading system [Mankin et al, Journal of Bone & Joint Surgery - American Volume, 1971, 53, 523-37] as shown below.

Category Grade
1. Structure
a. Normal 0
b. Surface irregularity 1
c. Pannus and surface irregularity 2
d. Clefts to transitional zone 3
e. Clefts to radial zone 4
f. Clefts to calcified zone 5
g. Complete disorganization 6
2. Cells
a. Normal 0
b. Diffuse hypercellularity 1
c. Cloning 2
d. Hypocellulariry 3
3. Safiranirt-O staining
a. Normal 0
b. Slight reduction 1
c. Modest reduction. 2
d. Severe reduction 3
e. No dye noted 4
4. Tidemark integrity
a. Intact - 0
b. Crossed by blood vessels 1
Evaluation in the HLA-B27 Rat model of arthritis.
[0100] Representative compounds are evaluated in the HLA-B27 rat standard pharmacological test procedure which emulates arthritis in humans. The following briefly describes the procedure used. Male HLA-B27 rats are obtained from Taconic and
30

WO 2005/121076

PCT/US2005/017183

provided unrestricted access to a food

(PMI Lab diet 5001) and water. Rats are dosed

subcutaneously once per day with either vehicle (50% DMSO / 50% lx Dulbecco's Phosphate Buffered Saline) or test compound (0.1 to 10 mg/kg) for at least one week. Joint scores and histology are evaluated as described above for the Lewis rat model of adjuvant-induced arthritis.
Evaluation in the collagen induced arthritis models.
[0101] Compounds are evaluated in BALB/c mice, 6-8 weeks of age, in which arthritis is induced by monoclonal antibodies raised against type n collagen, plus lipopolysaccharide (LPS). The animals were administered intravenously with a combination of 4 different mAbs totalling 4 mg/mouse on day 0, and followed by

intravenous

25 µg of LPS 72 hours later (day 3). From day 3, one hour after LPS

application,1 tested compounds are give orally once daily for 15 days. For each animal, increase in volume of both hind paws is measured using a plethysmometer with water cell (12 mm diameter) on days 0,5, 7,10,14 and 17. Percent inhibition of increase in volume is calculated.
Evaluation in in vivo models of carcinogeneisis
[0102] The ability of compounds of this invention to treat and inhibit various
malignancies or hyperprolific disorders can be evaluated in standard pharmacological
test procedures that are readily available in the literature, and include the following two
procedures.
[0103] Breast cancer. Athymic nu/nu (nude)' mice are obtained ovariectomized from Charles River Laboratories (Wilmington, MA). One day prior to rumor cell injection, animals are implanted with time-release pellets containing 0.36-1.7 mg 17 ß-estradiol (60 or 90 day release, Innovative Research of America, Sarasota, FL) or a placebo. The pellet is introduced subcutaneously into the intrascapular region using a 10-gauge precision trochar. Subsequently, mice are injected subcutaneously into the breast tissue with either lx107 MCF-7 cells or lx107 BG-1 cells. The cells are mixed with an equ|al volume of matrigel, a basement membrane matrix preparation to enhance tumor establishment. Test compounds can be evaluated either by dosing one day after tumor cell implantation (inhibition regimen) or after tumors have reached a certain size

(treatment regimen). Compounds are

administered either intraperitoneally or orally in a

31

WO 2005/121076

PCT7US2005/017183

vehicle of 1 % tween-80 in saline each day. Tumor size is evaluated every three or seven days.
[0104] Colon cancer. The ability to treat or inhibit colon cancer can be evaluated in the test procedure of Smirnoff [Oncology Research, 1999,11, 255-64].
Evaluation of neuroprotection in two in vivo test procedures
[0105] Transient global ischemia in the Mongolian gerbil. The effect of test compounds on preventing or treating brain injury in response to oxygen deprivation/reperfusion can be measured using the following test procedure.
[0106] Female Mongolian gerbils (60-80 g; Charles River Laboratories, Kingston, NY) are housed in the Wyeth-Ayerst animal care facility (AAALAC certified) with a 12-hour light, ,12-hour dark photoperiod and free access to tap water and a low-estrogen casein diet (Purina; Richmond, IN). After acclimation (3-5 days), gerbils are anesthetized with isoflurane (2-3% mixture with O2), ovariectomized (Day 0). Beginning the following morning (Day 1), gerbils are treated subcutaneously each day with either vehicle (10% ETOH/corn oil), 17 ß-estradiol (1 mg/kg) or an experimental compound (0.1-20 mg/kg). On Day 6, gerbils (n-4-5/group) are anesthetized with isoflurane, the common carotid arteries visualized via a mid-line neck incision and both arteries simultaneously occluded for 5 minutes with non-traumatic micro aneurysm clips. After occlusion, the clips are removed to allow cerebral reperfusion and the neck incision closed with wound clips. All animals are fasted overnight prior to the global ischemia surgery, a step that facilitates consistent ischemic injury. On Day 12, gerbils are exposed to a lethal dose of CO2, and the brains frozen on dry ice and stored at -80 °C.
[0107] The degree of neuronal protection is evaluated by in situ hybridization analysis of neurogranin mRNA. Briefly, 20 µm coronal cryostat sections are collected on gelatin-coated slides, dried and stored at -80 °C. At the time of processing, the desiccated slide boxes are warmed to room temperature, the slides postfixed in 4% paraformaldehyde, treated with acetic anhydride and then delipidated and dehydrated with chloroform and ethanol. Processed section-mounted slides are then hybridized with 200 µl (6xl06 DPM/ slide) of an antisense or sense (control) riboprobe for Neurogranin (35S-UTP-labeled NG-241; bases 99-340). in a 50% formamide hybridization mix and incubated overnight at 55 °C in a humidified slide chamber without coverslipping. The following morning, the slides are collected in racks, immersed in 2xSSC (0.3 M NaCl, 0.03 M sodium citrate; pH 7.0) / 10 mM DTT, treated with RNase A (20 µg/ml) and
32

WO 2005/121076 PCT/US2005/017183
washed (2 x 30 min) at 61 °C in 0.1x SSC to remove nonspecific label. After dehydration, the slides are opposed to BioMax (BMR-1; Kodak) X-ray film overnight.
[0108] The level of neurogranin hybridization signal is used to quantitatively assess the degree of neuronal loss in the CA1 region after injury and to evaluate the efficacy of 17 ß-estradiol and experimental compounds. Neurogranin mRNA is selected for these studies because it is highly expressed in the hippocampal neurons including CA1, but absent in glia and other cell types present in this brain region. Therefore, measurement of the amount of neurogranin mRNA present represents surviving neurons. Relative optical density measurements of neurogranin hybridization signal are obtained from film autoradiograms with a computer based image analysis system (C-Imaging Inc., Pittsburgh, PA). The results from 6 sections (40 urn apart) per animal are averaged and statistically; evaluated. Numerical values are reported as the mean ± SEM. One-way analysis of variance is used to test fordifferences in the level of neurogranin mRNA and all statements of non-difference in the results section imply that p>0.05.
[0109] Middle cerebral artery occlusion in mice. Neuroprotection can be evaluated according to the test procedures described by Dubai [see, Dubai et al, Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1952-1957, Dubai et al, Journal ofNeuroscience, 1999,19, 6385-6393].
Ovulation inhibition standard pharmacological test procedure
[0110] The test procedure is'used to determine whether test compounds can inhibit or change the timing of ovulation. It can also be used to determine the number of oocytes ovulated [Lundeen et at, J. Steroid Biochm, Mol Biol, 2001, 78, 137-143].
Transplantation Rejection
[0111] To test the ability of the test compounds to prevent transplant rejection. Compounds can be tested in animal models of heart transplantation (Stetson et al,
Circulation, 2001, 104:676-682 or transplant atherosclerosis (Deitrich et al,
i
Arterioscler. Thromb. Vase BioL, 2000, 20:343-352; Lou etal9 Circulation, 1996, 94,
3355-3361.,
Prevention of Restenosis
[0112] The test procedure is

used to determine whether test compounds can

inhibit vascular smooth muscle cell proliferation after carotid artery injury similar to
33

WO 2005/121076 PCT?US2005/017183
what occurs after balloon angioplasty. The test compounds can be tested in animal models previously described (Karas et al, Circ Res., 2001, 89, 534-539; Cerek et al, Atherosclerosis, 1997, 131, 59-66.
Treatment of Myocardial Infarction
[0113] Test compounds can be tested in animal models of ischernia/reperfusion to determine whether they would inhibit cell death occurring during a myocardial infarction. The compounds can be tested in models described previously (Delyani et al, J. Mol & Cell Cardiology, 1996, 28, 1001-1008; Izumi et al., J. Clin, Invest., 2001, 108, 203-213; Chandrasekar et al, Circulation, 2001,103, 2296-2302).
Treatment for Myocarditis and Congestive Heart Failure

[0114] Test compounds can be tested in models of heart failure to determine whether compounds could be an effective therapy and improve cardiac function. Compounds can be tested in animals as described previously (Yokoseki et al., Circ. Res., 2001, 89,1-9; Wallen et al, Hypertension, 2000, 36, 774-779; Toshiaki et al, Circulation, 2001, 104,1094-1103). !
Treatment for Diabetes
i [0115] Test compounds can be tested in models of diabetes to determine their
effect on reversal of obesity and diet-induced insulin resistance. Compounds can be tested in animal models as previously described (Yuan et al, Science, 2001, 293:1673-1677.
34

WO 2005/121076

PCTYUS2005/017183

Treatment for Asthma
[0116] Pulmonary Inflammation Model, Sensitize mice with OVA emulsified

in alum on days 0 and 14 (ip injection),
On days 28 and 29, challenge with an aerosol of
OVA for 20 min (l%-5% OVA) and then on Day 30 the animals are sacrificed and harvest BAD and/or lung tissue for analysis of pulmonary inflammation.
[0117] Airway Hyperresponsiveness. This model is similar to that described

above however animals are challenged

on 3 consecutive days with an aerosol of OVA

and airway hyperresponsiveness is measured 48 h after the last challenge. BAJL can also be taken at this stage if required.
[0118] To look more directly at the effects of mast cells in conjunction with ER, may use a passive cutaneous anaphylaxis model in which IgE is injected into the ear and then 24 hours later inject DNP-HSA iv. Measure ear thickness and an early and late phase reaction. Furthermore, fix tissues in K2 and embed in Epoxy resin and cut lum sections. These can be stained for mast cells and quantitiate the degree of mast cell degranulation.
[0119] Based on the results obtained in the standard pharmacological test

procedures,
the compounds of this invention are selective anti-inflammatory compounds
described herein useful for the treatment and prevention of chronic inflammatory diseases without stimulating uterine and breast cell proliferation as found with classic estrogens.
[0120] Accordingly, the compounds of this invention are useful in treating or inhibiting osteoporosis and in the inhibition of bone dernineralization, which may result from an imbalance in a individual's formation of new bone tissues and the resorption of older tissues, leading to a net loss of bone. Such bone depletion results in a range of

individuals,

particularly in post-menopausal women, women who have undergone

bilateral oophorectomy, those receiving or who have received extended corticosteroid therapies, those experiencing gonadal dysgenesis, and those suffering from Cushing's syndrome. Special needs for bone, including teeth and oral bone, replacement can also be addressed using these compounds in individuals with bone fractures, defective bone structures, and those receiving bone-related surgeries and/or the implantation of prosthesis, "in addition to those problems described above, these compounds can be used in treatment or inhibition for osteoarthritis, hypocalcemia, hypercalcemia, Paget's disease, osteomalacia, osteohalisteresis, multiple myeloma and other forms of cancer having deleterious effects on bone tissues.
35

WO 2005/121076

PCT/US2005/017183

[0121] The compounds of this invention are also active in the brain and are
'i
therefore useful for inhibiting or treating Alzheimer's disease, cognitive decline, decreased libido, senile dementia, neurodegenerative disorders, depression,' anxiety, insomnia, schizophrenia, and infertility. The compounds of this invention are also useful in treating or inhibiting benign or malignant abnormal tissue growth including, glomerulosclerosis, prostatic hypertrophy, uterine leiomyomas, breast cancer, scleroderma, fibromatosis, endometriosis, endometrial cancer, polycystic ovary syndrome, endometrial polyps, benign breast disease, adenomyosis, ovarian cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, such as glioma or astioblastomia.
[0122] The compounds of this invention are cardioprotective and are antioxidants, and are useful in lowering cholesterol, triglycerides, Lp(a), and LDL levels; inhibiting or treating hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, peripheral vascular disease, restenosis, and vasospasm, and inhibiting vascular wall damage from cellular events leading toward immune mediated vascular damage.
[0123] The compounds of this invention are also useful in treating disorders
associated with inflammation or autoimmune diseases, including inflammatory bowel
'i disease (Crohn's disease, ulcerative colitis, indeterminate colitis), arthritis (rheumatoid
arthritis, spondyloarthropathies, osteo arthritis), pleurisy, ischemia/rep erfusion injury (e.g. stroke, transplant rejection, myocardial infarction, etc.)5 asthma, giant cell arteritis, prostatitis, uveitis, psoriasis, multiple sclerosis, systemic lupus erythematosus and sepsis.
[0124] The compounds of this invention are also useful in treating or inhibiting ocular disorders including cataracts, uveitis, and macular degeneration and in treating skin conditions such as aging, alopecia, and acne.
[0125] The compounds of this invention are also useful in treating or inhibiting metabolic disorders such as type-H diabetes, of lipid metabolism, appetite (e.g. anorexia nervosa and bulimia).
[0126] Compounds in this invention are also useful in treating or inhibiting bleeding disorders such as hereditary hemorrhagic telangiectasia, dysfunctional uterine bleeding, and combating hemorrhagic shock.
[0127] The compounds of this invention are useful in disease states where amenorrhea is advantageous, such as leukemia, endometrial ablations, chronic renal or hepatic disease or coagulation diseases or disorders.
36

WO 2005/121076 PCT/US2005/017183
These results suggest an anti-inflammatory role for the test compounds in terms of their ability to block inflammatory gene expression, with the desired selectivity in activity since no induction in uterine wet weights was observed.
[0128] All patents, publications, and other documents cited herein are hereby incorporated by reference in their entirety.
37

WO 2005/121076

PCT/US2005/017183

What is claimed:
1. A compound of the formula:

and pharmaceuticaily acceptable salts, hydrates and solvates thereof, wherein:
R1, R2, and R3 are each independently, hydrogen, halogen, alkyl, cycloalkyl, alkoxy, nitro, cyano, alkyltbio, CF3, GCF3 or OH; and
R4 is hydrogen, alkyl, alkenylj arylalkyl, cycloalkyl-methyl, or heterocyclyl-alkyl;
provided that at least one of R1, R2, R3, and R4 is other than H.
2. The compound of claim 1 wherein R4 is H.
3. The1 compound of claim 1 or 2 wherein at least one of R1, R2, and R3 is halogen,
alkyl, cycloalkyl, alkoxy, nitro, cyano, alkylthio, CF3, OCF3 or OH.
4. The compound of any one of claims 1 to 3 wherein R1 and R2 are each
independently H, halogen, alkyl, alkoxy, cyano, CF3 or OH.
5. The compound ofany one of claims 1 to 4 wherein R1 and R2 are the same.
6. The compound of any one of claims 1 to 5 -wherein R3 is H, alkyl, alkenyl,
alkylaryl or heterocyclyl-methyl.
7. The compound of any one of claims 1 to 6 wherein R1 and R2 are each H, halogen, alkyl or alkoxy.
38

WO 2005/121076

PCT/US2005/017183

8. The compound of any one of claims 1 to 7 wherein R3 is alkyl, allyl or benzyl.
9 . The compound of any one of claims 1 to 5 wherein R1 and R2 are each H and R3
is halogen, alkyl, alkoxy, cyano, CF3 or OH.
10 . The compound of claim 9 wherein R1 and R2 are each H and R3 is halogen, alkyl,
or alkoxy.
11 . The compound of any one of claims 1 to 10 wherein R4 is H.
12 . The compound of any one of claims 9 to 11 wherein R3 is methyl or methoxy.
13 . The compound of claim 1 that is:
2-[(2-methoxyphenyl)(l-naphthyl)methyl]malonorjitrile,
2- [(3 -methpxyphenyl) (1 -naphth.yl)methyl]malononitrile,
2-[(2-methylphenyl)(l-naphthyl)methyI]malononitrile,
1
2- [ (4~methylphenyl) (1 -naphthyl)methyl]malononitrile,
1
2-t(4~methoxyphenyl)(l-naphthyl)methyl]malonomtrile, 2-[(2-methoxyphenyl)(l-naphtliyl)methyl]-2-methyhnalononitrile, or 2-[di(l-naphthyl)methyl]malononitrile.
14 . A pharmaceutical composition comprising a compound of any one of claims 1 to
13 and a pharmaceutically acceptable excipient, diluent or carrier.

15 . A method of treating or inhibiting chronic inflammatory disease in a mammal in
need thereof, which comprises administering to said mammal an effective amount of a
compound of any one of claims 1 to 13.
16 . A method of treating or inhibiting rheumatoid arthritis, spondyloarthropathies,
osteoarthritis, psoriatic arthritis, or juvenile arthritis in a mammal in need thereof, which
comprises administering to said mammal an effective amount of a compound of any one
of claims 1 to 13.
39

WO 2005/121076 PCT/US2005/017183
17 . A method of treating or inhibiting inflammatory bowel disease, Crohn's disease,
ulcerative colitis, or indeterminate colitis in a mammal in need thereof, which comprises
administering to said mammal an effective amount of a compound of any one of claims 1
to 13.
18 . A method of treating or inhibiting psoriasis in a mammal in need thereof, which
comprises administering to said mammal an effective amount of a compound of any one
of claims 1 to 13.
19 . A method of treating or inhibiting asthma or chronic obstructive pulmonary
disease in a mammal in need thereof, which comprises administering to said mammal an
effective amount of a compound of any one of claims 1 to 13.
20. A method of treating or inhibiting stroke, ischemia, or reperfusion injury in a
mammal in need thereof, which comprises administering to said mammal an effective

amount of a compound of any one of claims 1 to 13.
21 . A method of lowering cholesterol, triglycerides, Lp(a), and LDL levels;
inhibiting or treating hypercholcsteremia, hyperlipidemia, cardiovascular disease,

atherosclerosis, acute coronary syndrome, peripheral vascular disease, restenosis, or vasospasm in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of any one of claims 1 to 13.
22 . A method of treating or inhibiting Alzheimer's disease, cognitive decline, or
senile dementia in a mammal in need thereof, which comprises administering to said

mammal an effective amount of a compound of any one of claims 1 to 13.
23 . A method of treating or inhibiting type IT diabetes in a mammal in need thereof,
which comprises administering to said mammal an effective amount of a compound of
any one of claims 1 to 13.
24 . A method of treating or inhibiting sepsis in a mammal in need thereof, which
comprises administering to said mammal an effective amount of a compound of any one

of claims 1 to 13.
40

WO 2005/121076 PCT/US2005/017183
25. The use of a compound of any one of claims 1 to 13 in the manufacture of a
medicament for treating or inhibiting chronic inflammatory disease, rheumatoid arthritis,
spondyloarthropathies, osteoarthritis, psoriatic arthritis, juvenile arthritis, inflammatory
bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, psoriasis, asthma,
chronic obstructive pulmonary.disease, stroke, ischemia, reperfusion injury,
hypercholesteremia, hyperlipidemia, cardiovascular disease, atherosclerosis, acute
coronary syndrome, peripheral vascular disease, restenosis, vasospasm, Alzheimer's
disease, cognitive decline, senile dementia, type n diabetes, sepsis, or for lowering
cholesterol, triglycerides, Lp(a) or LDL levels, in a mammal.
41
The present invention concerns compounds of formula (I) where R1, R2, R3 and R4 are defined in the specification.